News

Circulating tumor DNA (ctDNA) monitoring is clinically valid in predicting whether patients with unresectable, metastatic BRAF-mutant melanoma will benefit from dabafenib (Tafinlar) alone or in combination with trametinib (Mekinist).

Several key abstracts presented at the 2019 ASCO Annual Meeting demonstrated practice-changing potential in the prostate cancer field, said Celestia S. Higano, MD, FACP.

Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic, according to a presentation by Charles M. Rudin, MD, PhD, at the 2019 International Lung Cancer Congress.

Many adolescent and young adult cancer survivors struggle in the post-cancer period. Oncology nurses can help ensure that they don’t fall through the cracks.

The Food and Drug Administration granted a priority review for a new drug application for tazemetostat. The drug will be used to treat a rare kind of soft tissue sarcoma that mainly affects young adults.

After months of debate, the Food and Drug Administration announced that they will be taking action to protect women from breast implant-associated anaplastic large cell lymphoma.

Nurse coordinators and other healthcare professionals must work together to provide comprehensive lung cancer screening programs.

The Food and Drug Administration (FDA) approved rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) for the treatment of blood cancers.

A recent study found that in some parts of the United States, more patients with cancer are treated by nurse practitioners than medical oncologists.

Immunotherapy has drastically changed the treatment landscape for non-small cell lung cancer, but how can practitioners decide who should get frontline chemotherapy, too?

Selective inhibitors for patients with non–small cell lung cancer with rare oncogenic drivers are showing high response rates in clinical trials, explained one expert.

Molecular testing has led to monumental strides in the field of ovarian cancer, offering women with the disease more personalized treatment options.

Oncology nurses may experience a high level of bullying from their peers, but steps can be taken to improve the environment of the workplace.

Patients with high-risk mantle cell lymphoma are likely to have their disease relapse, making investigations into novel treatments, such as CAR T-cell therapy, important.

Nurses, patients, and caregivers can now have crucial information regarding medical devices sent directly to their smartphone.

Some patients with advanced ovarian cancer may be better candidates for primary debulking surgery, while others should start chemotherapy.

Light therapy can be used to prevent oral mucositis in patients with cancer, according to one expert.

Despite most wishing to die at home, nearly a third of patients with cancer die in the hospital. Goals-of-care discussions with nurses and other providers can help bring that number down.

Multiple Initiatives Contribute to ESPY Week Fundraising

An oncology nurse started a grassroots campaign that brought together community members and patients on the oncology unit.

A person’s HIV status should not be the sole reason they are excluded from a cancer clinical trial, according to recent research.

A pediatric oncology nurse’s experience came full circle following her own bladder cancer diagnosis, followed by serving as a caregiver to her husband who faced the same disease 6 years later.

Symptom management and proper risk stratification are two crucial ways to improve the care of patients with myeloproliferative neoplasms, according to one expert.

By better understanding the subtypes of breast cancer, clinicians can create more personalized and effective treatment plans for patients with breast cancer.

After her sister passed away from hepatocellular carcinoma, Andrea Wilson started Blue Faery: The Adrienne Wilson Liver Cancer Association.

When it comes to molecular testing to advance the field of lung cancer, coordinated efforts between providers—and institutions nationwide—are key.

CLR 131, a targeted, molecular radiotherapy, showed a 33% overall response rate in patients with diffuse large B-cell lymphoma.

Now that the CD19-targeted CAR T-cell therapies axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah) have shown durable responses in the relapsed/refractory settings of non-Hodgkin lymphoma, researchers are hopeful that earlier exposure may heighten the curative potential of the modality, explained Mazyar Shadman, MD, MPH.

Now that patients have more drug options to treat myeloma, quality of life is becoming more important, said one expert.

An expert discusses the cardiac toxicity of ABP 980, a trastuzumab biosimilar, in the breast cancer space.